The Ospedale Niguarda, one of the most prominent Hospitals in Italy, is now completing the internal process and expectations are for the contract to be formalized in the very next few weeks.

The choice of ASTar by the Microbiology Laboratory comes after a multi-vendor evaluation conducted at the beginning of 2024 and has been based on the very positive experience in terms of ease of use, workflow and strong clinical results displayed in the management of critical patients affected by sepsis.

“We are very pleased with this success in another key Italian Institution like Ospedale Niguarda that had the implementation of rAST as one of their key projects for 2024. ASTar continues to be the preferred technical choice in the country, a path we are counting to continue and strengthen going forward” said Franco Pellegrini, VP Sales EMEA at Q-linea.